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Abstract
Background: The hypergeometric enrichment analysis approach typically fares poorly in feature-selection stability
due to its upstream reliance on the t-test to generate differential protein lists before testing for enrichment on a
protein complex, subnetwork or gene group.
Methods: Swapping the t-test in favour of a fuzzy rank-based weight system similar to that used in network-based
methods like Quantitative Proteomics Signature Profiling (QPSP), Fuzzy SubNets (FSNET) and paired FSNET (PFSNET)
produces dramatic improvements.
Results: This approach, Fuzzy-FishNET, exhibits high precision-recall over three sets of simulated data (with simulated
protein complexes) while excelling in feature-selection reproducibility on real data (based on evaluation with
real protein complexes). Overlap comparisons with PFSNET shows Fuzzy-FishNET selects the most significant
complexes, which are also strongly class-discriminative. Cross-validation further demonstrates Fuzzy-FishNET
selects class-relevant protein complexes.
Conclusions: Based on evaluation with simulated and real datasets, Fuzzy-FishNET is a significant upgrade of
the traditional hypergeometric enrichment approach and a powerful new entrant amongst comparative proteomics
analysis methods.
Keywords: Proteomics, Networks, Bioinformatics, GSEA, QPSP, SNET, FSNET, PFSNET, Renal Cancer
Background
Mass spectrometry (MS)-based proteomics is becoming
increasingly important in contemporary biological and
clinical research [1]. Yet, despite significant techno-
logical advancement marking quantum leaps in protein
extraction and spectra-acquisition [2–4], data reliability
issues in MS-based proteomics persist: the primary issues
being incomplete proteome coverage and inter-sample
protein identification inconsistency [5]. These problems
are not yet resolved satisfactorily on current proteomics
paradigms [6–8]. Moreover, with the advent of brute-force
spectra capture strategies e.g. Data-Independent Acquisi-
tion (DIA) [9, 10], increased noise becomes an inadvertent
consequence, and contribute yet another layer of com-
plexity [2].
Proteomics allows the simultaneous expressional
profiling of thousands of proteins (although leaving
thousands more which remain undetected). The first
order of business is usually to identify proteins which
are strongly and consistently differential, with the expec-
tation that these are phenotypically relevant. This process
is known as “feature selection”, and helps to concentrate
analysis on a smaller feature (protein) set which is easier
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to study, understand and validate experimentally [11].
Unlike animal models or cell lines, clinical samples are
highly heterogeneous, reflecting different disease etiolo-
gies and genetic backgrounds amongst unique individuals
[12]. Heterogeneity, compounded with the fact that diffe-
rent proteins being identified between samples [13], and
possible quantification accuracy issues [14] means that in
practical deployment, it is difficult to make reliable identi-
fication of useful biomarkers or drug targets during ana-
lysis of clinical data. Hence, more sophisticated and robust
analytical methods are required.
Contextualization at the level of subnets, or more
specifically, protein complexes, can resolve proteomic
coverage and consistency issues [15–18]. Use of protein
complexes as features for feature-selection instead of pre-
dicted clusters from reference networks, is a more power-
ful approach as protein complexes are enriched for
biological signal [19]. However, use of protein complexes
alone (despite its high biological signal enrichment) is
insufficient: the nature of the statistical analysis method
is also equally important. The hypergeometric enrichment
(HE) test is commonly used in many areas of biological
research from testing for functional enrichment [20–25]
to testing for over-representation of genes in predicted
subnetworks [26]. Yet, despite its wide use, even when
used with protein complexes, HE does poorly, particularly
in terms of feature-selection stability [16].
HE is actually a two-part test (see Methods). But its reli-
ance on the t-test to generate a differential protein list for
subsequent enrichment analysis based on the hypergeo-
metric test is a known contributing factor towards its high
instability [27, 28], and is demonstrated again in recent
work [16]. We may redesign HE using elements of design
that have worked well in other techniques.
QPSP, and the rank-based network approaches (RBNAs),
SNET (SubNET) [29], FSNET (Fuzzy SNET) and PFSNET
(Paired FSNET) [30] have been shown to be highly stable
and robust, these techniques are similar in that they use a
fuzzy weighting system on proteins ranked by expression
[31] (see Methods).
By incorporating the fuzzy weighting system into HE, and
doing away with upstream t-test differential protein pre-
selection, a new spin on the original HE technique, Fuzzy-
FishNET, is introduced here. Its name comes from the in-
corporation of the fuzzy weighting system in QPSP/FSNET/
PFSNET with the one-sided Fisher’s exact test (equivalent
to the hypergeometric test). Fuzzy-FishNET is evaluated
based on precision and recall on three simulated data-
sets, and also its stability/reproducibility on real data.
Methods
Simulated proteomics datasets — D.1.2, D2.2 and RC1
Two simulated proteomics datasets, D1.2 and D2.2, from
the study of Langley and Mayr are used [32]. D.1.2 is
obtained from a study of proteomic changes resulting
from addition of exogenous matrix metallopeptidase
(3 control, 3 test) while D2.2 is obtained from a study of
hibernating arctic squirrels (4 control, 4 test). Protein
quantification in both studies is based on spectral counts.
For both D1.2 and D2.2, 100 simulated datasets each
with 20% randomly generated differential features are
generated. The 20% threshold is arbitrary, for D1.2 and
D2.2, this corresponds to 177 and 710 differential pro-
teins respectively. For a given feature measured amongst
samples derived from two different sample classes A and
B, the effect size is the magnitude of the inter-class
difference e.g. the differences of the means amongst sam-
ples derived from classes A and B. Here, the effect sizes of
these 20% differential features are randomly selected from
one out of five possibilities or p (20%, 50%, 80%, 100%
and 200%), increased in one class and not in the other,
and expressed as:
SCi;j
0 ¼ SCi;j  1þ pð Þ
where SCi,j and SCi,j’ are respectively the original and
simulated spectral count from the jth sample of protein i.
RC1 comes from the 12 controls from the renal cancer
(RC) dataset (see below). As with D1.2 and D2.2, 20%
random proteins are randomly selected as differential,
an effect size sampled from one of 5 possibilities, and
inserted in only half of the controls, thus creating 6 con-
trol and 6 artificial test samples. This is also repeated
100 times to generate 100 simulated datasets.
Proteomics dataset — renal cancer (RC)
The renal cancer (RC) study of Guo et al. [2] is derived
from six pairs of non-tumorous and tumorous clear-cell
renal carcinoma (ccRCC) tissues based on the SWATH
spectra-acquisition method. The six sample pairs are
examined twice, as two different technical batches.
All SWATH spectra maps are analyzed using Open-
SWATH [9] against a spectral library containing 49,959
reference spectra for 41,542 proteotypic peptides from
4,624 reviewed SwissProt proteins [2]. The library is
compiled via library search of spectra captured in DDA
mode (linking spectra mz and rt coordinates to a library
peptide). Proteins are quantified via spectral count.
Protein complexes (subnets)
Although subnets or clusters are predictable from large
biological networks, real biological complexes are enriched
for biological signal, far outperforming predicted com-
plexes/subnets from reference networks [19, 31, 33, 34].
Here, known human protein complexes derived from the
CORUM database are used [35].
To avoid high fluctuation in the test statistics used by
some of the methods considered here (e.g. QPSP),
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complexes with at least 3 proteins that were identified
and measured in the proteomics screen are retained
(1363 complexes)
Hypergeometric-enrichment (HE)
HE is a frequently used form of protein complex/subnet-
work evaluation and consists of two steps [5]: First,
differential proteins are identified using the two-sample
t-test [36]. This is followed by a hypergeometric test
where given a total of N proteins (with B of these belong-
ing to a complex) and n test-set proteins (i.e., differential),
the exact probability P that b or more proteins from
the test set are associated by chance with the complex is
given by [37]:












The sum P(X ≥ b) is the p-value of the hypergeometric
test.
Gene-set enrichment analysis (GSEA)
The direct-group (DG) analysis approach, Gene-Set
Enrichment Analysis, or GSEA is developed as a more
powerful alternative to HE, as it obviates the t-test-based
protein pre-selection step. In GSEA, a complex is tested
by comparing the distribution of constituent protein ex-
pression between phenotype classes against that of pro-
teins outside the complex using a Kolmogorov-Smirnov
(KS) statistic [38].
Denoting proteins in the complex as the set D and pro-
teins outside the complex as the set D’, the KS-statistic
KSD,D‘is expressed as:
KSD;D ¼ maxx F1;D xð Þ−F2;D0 xð Þ
 
where F1,D(x) and F2,D *(x) are respectively the number
of proteins in D and D’ that whose rank is higher than
the rank x. The null hypothesis is rejected at an alpha
of 0.05 if
KSD;D0≥c alphað Þ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
D þj jD0 
jDj  jD0 j
s
where c(alpha) is the critical value at a given alpha level.
Here, at an alpha of 0.05, c(alpha) = 1.36.
Quantitative proteomics signature profiling (QPSP)
In QPSP, each sample is sorted based on abundance.
The most abundant proteins above a certain percentile
(the value is denoted as alpha1) are first selected. A
second percentile value (defined as alpha2) is then used to
extend the protein list [30]. To penalize lower-ranked
proteins below alpha1 and above alpha2, proteins are
assigned interpolated weights based on their ranks.
Alpha1 and alpha 2 are typically set as the top 10%,
and top 20% ranks respectively. Rank-based weighting is
achieved via discretization of the ranks from top 10-20%
into four bins: 10–12.5% (weight 0.8), 12.5% to 15%
(0.6), 15–17.5% (0.4), 17.5 to 20% (0.2). All other proteins
beyond alpha2 (viz. remaining proteins) have a weight of 0
(and are thus ignored). Proteins above alpha1 are assigned
a full weight of 1.
Given each sample, a vector of hit-rates is generated
by considering the overlaps of the proteins (given their
weights) against a vector of complexes. Given a sample
in class A (SA) and a vector of complexes of length n,
for each complex Ci in the complex vector, the hit-rate
is the intersection of proteins in SA and Ci, modulated
by the weight, over the total number of proteins in Ci.
Let the hit-rate for SA in Ci be H(SA, Ci). Therefore, the
vector of hit-rates for sample SA is HSA = 〈H(SA, C1)…,
H(SA, Cn)〉. This vector of hit-rates signifies the sample’s
signature profile based on complexes.
QPSP works with simple two-sample t-test. For each
complex C in the complex vector, two lists are compared
against each other, HA = 〈H(A1,C),…, H(Am,C)〉 and
HB = 〈H(B1,C),…, H(Bn,C)〉, where A and B are phenotype
classes of lengths m and n respectively. The t-statistic,
t_score, between HA and HB is computed by:









m−1ð ÞSHA2− n−1ð ÞSHB2
mþ n−2
s
If t_score for Ci is significant (i.e. its associated p-value
falls below 0.05), then Ci is considered differential.
SNET/FSNET/PFSNET
In SNET, given a protein gi and a tissue pk, let fs(gi,pk) = 1,
if the protein gi is among the top alpha percent (default =
10%) most-abundant proteins in the tissue pk; and = 0
otherwise.
Given a protein gi and a class of tissues Cj, let
β gi;Cj






That is, β(gi,Cj) is the proportion of tissues in Cj that
have gi among their top alpha percent most-abundant
proteins.
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Let score(S,pk,Cj) be the score of a protein complex S
and a tissue pk weighted based on the class Cj. It is
defined as:




   β gi;Cj 
The function fSNET(S, X,Y,Cj) for some complex S is a
t-statistic defined as:
f SNET S;X;Y ;Cj







var S;Y ;Cjð Þ
Yj j
r
where mean(S,#,Cj) and var (S,#,Cj) are respectively the
mean and variance of the list of scores {score(S,pk,Cj) | pk
is a tissue in #}.
The complex S is considered differential (weighted
based on Cj) in X but not in Y if fSNET(S,X,Y,Cj) is at the
largest 5% extreme of the Student t-distribution, with de-
grees of freedom determined by the Welch-Satterwaite
equation.
Given two classes C1 and C2, the set of significant
protein complexes returned by SNET is the union of
{S | fSNET(S,C1,C2,C1) is significant} and {S | fSNET(S,C2,C1,C2)
is significant}; the former being complexes that are sig-
nificantly consistently highly abundant in C1 but not C2,
the latter being complexes that are significantly consis-
tently highly abundant in C2 but not C1.
FSNET is identical to SNET, except in one regard:
For FSNET, the definition of the function fs(gi,pk) is
replaced such that fs(gi,pk) is assigned a value between 1
and 0 as follows: fs(gi,pk) is assigned the value 1 if gi is
among the top alpha1% (default = 10%) of the most-abun-
dant proteins in pk. It is assigned the value 0 if gi is
not among the top alpha2% (default = 20%) most-
abundant proteins in pk. The range between alpha1%
and alpha2% is divided into n equal-sized bins (default
n = 4), and fs(gi,pk) is assigned the value 0.8, 0.6, 0.4,
or 0.2 depending on which bin gi falls into in pk. This
tiered weighting system is termed fuzzification.
A test statistic fFSNET is defined analogously to fSNET. Given
two classes C1 and C2, the set of significant complexes
returned by FSNET is the union of {S | fFSNET(S,C1,C2,C1)
is significant} and {S | fFSNET(S,C2,C1,C2) is significant}.
For PFSNet, the same fs(gi,pk) function as in FSNet is
used. But it defines a score delta(S,pk,X,Y) for a complex
S and tissue pk wrt classes X and Y as the difference of
the score of S and tissue pk weighted based on X from
the score of S and tissue pk weighted based on Y. More
precisely: delta(S,pk,X,Y) = score(S,pk,X) – score(S,pk,Y).
If a complex S is irrelevant to the difference between
classes X and Y, the value of delta(S,pk,X,Y) is expected
to be around 0. So PFSNet defines the following one-
sample t-statistic:
f PFSNET S; X; Y ; Zð Þ ¼
mean S;X;Y ;Zð Þ
se S;X;Y ;Zð Þ
where mean(S, X, Y, Z) and se(S, X, Y, Z) are respectively
the mean and standard error of the list {delta(S,pk,X,Y) |
pk is a tissue in Z}. The complex S is considered signifi-
cantly consistently highly abundant in X but not in Y if
fPFSNet(S, X, Y, X ∪ Y) is at the largest 5% extreme of
the Student t-distribution.
Given two classes C1 and C2, the set of significant
complexes returned by PFSNet is the union of {S |
fPFSNet(S,C1,C2,C1 ∪ C2) is significant} and {S |
fPFSNet(S,C2,C1,C1 ∪ C2) is significant}; the former being
complexes that are significantly consistently highly
abundant in C1 but not C2, and vice versa.
Fuzzy-FishNET
In Fuzzy-FishNET, a gene, gi, in sample pk, is assigned a
weight ff(gi,pk) between 5 and 0 as follows: ff(gi,pk) is
assigned the weight value 5 if gi is among the top
alpha1% (default = 10%) of the most-abundant proteins
in pk (Fig. 1). To boost sensitivity, a second alpha level,
alpha2 is defined between the range top 10–20%. To
account for the higher level of uncertainty for proteins in
this region, weights are assigned based on ranks. To do
this, proteins within alpha2 are divided into n equal-sized
bins (default =4), and ff(gi,pk) and assigned a weight
of 4, 3, 2, or 1 depending on which bin gi falls into in pk.
Proteins that fall below the top 20% are assigned weights
of 0.
For a complex S, and samples in class J, Cj, and samples
in class k, Ck, the sum of weights can be expressed in a
contingency table (Table 1) as shown below:
where a and c are the sum of weights for samples in
class Cj and Ck mappable to proteins within complex S
respectively, b and d are the sum of weights across sam-
ples in class Cj and Ck that are missed for proteins in
complex S respectively. The Fisher exact probability p of











¼ aþ bð Þ! cþ dð Þ! aþ cð Þ! bþ dð Þ!
a!b!c!d!n!
The Fisher exact probability p is also the hypergeo-
metric probability of observing this particular arrange-
ment of the data, assuming the given marginal totals,
on the null hypothesis that both Cj and Ck have similar
distributions of top alpha proteins across their class
members mappable to constituent proteins belonging
to complex S [37].
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The p-value is calculated in a similar manner as in HE,
as the sum of probabilities of obtaining an observation
greater than or equal to a.
Performance benchmarks (simulated data)
In simulated data, differential proteins are are defined
a priori and used to construct pseudo-complexes at
various levels of purity (i.e., the proportion of significant
proteins in the complex).
Proteins in the same complex are expected to be expres-
sionally correlated. To incorporate this principle in pseudo-
complex generation, a Euclidean distance is calculated for
all differential protein pairs across all samples. These are
then clustered via Ward’s linkage. The differential proteins
are reordered such that those with similar expression
pattern are adjacent to each other. This reordered list is
then split at regular intervals to generate 20, 101 and 62
differential pseudo-complexes for D1.2,D2.2 and RC1 re-
spectively. An equal number of non-differential proteins
are randomly selected, reordered based on expressional
correlation, and then split to generate an equal number of
non-differential pseudo-complexes.
The purity of the pseudo-complexes is lowered by
decreasing the proportion of differential proteins [39].
This makes it harder for a differential pseudo-complex
to be detected. So lowering purity tests for robustness
and sensitivity. Here, purity is tested at three levels:
100%, 75% and 50%. At 100% purity, simulated complexes
are comprised solely of differential proteins. These are
randomly swoped out at lower purity levels; e.g. at 75%
purity, 25% constituent differential proteins are randomly
replaced with non-differential ones.
The differential and non-differential pseudo-complexes
are combined into a single complex vector, which can
be used for precision and recall-based evaluation of
complex-based feature-selection methods:
Precision ¼ TP
TP þ FP ;Recall ¼
TP
TP þ FN
where TP, FP and FN are the True Positives, False Posi-
tives and False Negatives respectively. Since precision and
1 
2


















Fig. 1 Schematic of Fuzzy-FishNET A vector of complexes are compared against protein weights (based on expression ranks). For each complex,
a contingency table may be constructed based on the sum of weights between normal and cancer samples, and a p-value calculated based on
the Fisher’s exact test
Table 1 A typical 2 x 2 contingency table
In complex S Not in Complex S Marginals
Samples in Class J (Cj) a b a + b
Samples in Class
K(Ck)
c d c + d
Marginals a + c b + d a + b + c + d = n
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recall are both important performance measures, they can
be combined to generate an average. A common way of
doing this is the F-score (FS) which is the harmonic mean
between precision and recall:
Fs ¼ 2  Precision  RecallPrecision þ Recall
Performance benchmarks (real data)
On real data, differential complexes are not known a
priori, so direct precision-recall analysis is not pos-
sible. Instead, one may test for reproducibility/stability
[31, 34, 39].
Reproducibility can be gauged based on the overlaps
between technical replicates. To compare the technical
replicates in RC, let T1 and T2 be the significant com-
plexes selected by independently applying a given net-
work method on the two replicates. Then reproducibility
may be measured as overlaps based on the Jaccard
coefficient (J):
J ¼ T 1∩T 2j jjT 1∪T 2j
This comparison may not be sufficiently robust and
doesn’t allow evaluation at small sample sizes. So, one
may perform resampling at different levels (resampling
sizes of 4, 6 and 8) and generate a binary matrix for each
method, where a value of 1 indicates significance at a
significance level of 0.05 and 0 otherwise per complex.
The binary matrix may be analyzed in 2 ways: Row
summation to evaluate the numbers of predicted diffe-
rential complexes and column summation to evaluate the
stability of predicted differential complexes [34].
Cross-validation (real data)
To demonstrate that Fuzzy-FishNET selects class-relevant
differential complexes and only works when sample classes
are real, cross-validation is performed 1000 times in two
scenarios: where real classes exist(A) and where classes are
shuffled/randomized (B) in RC. In each instance, half the
data is used for feature-selection using Fuzzy-FishNET.
A quarter of the remaining data is used for training, and
the final quarter, validation. The classifier used is the
deterministic Naïve Bayes method [40]. Cross-validation
accuracy (CVAccuracy) is defined as:
CVAccuracy ¼ Number of correct class assignments
Total size of validation set
A good feature-selection approach will select features
that can build highly accurate prediction models when
true class labels are present. But if the class labels are
shuffled, then this is expected to lead to strong decrease
in predictive performance.
Results and discussions
F-score comparisons (Simulated datasets)
The F-score distributions suggest that under noisier
conditions (purity below 75%), Fuzzy-FishNET is an im-
provement over conventional HE and GSEA methods
but overall appears to be a weaker method than earlier
complex-based feature selection methods such as PFSNET
(Fig. 2).
HE typically has the worst F-scores over all methods
surveyed but in actuality, does very well in precision
(Additional File 1) but falls short largely in recall
(Additional File 2). Although GSEA is developed to
address HE’s reliance on the unstable differential protein
pre-selection step (e.g. based on the t-test), it is only
powerful when purity is at 100%. If purity drops to 75%
and below, GSEA’s F-score distributions quickly plum-
mets. At purity of 50%, GSEA becomes the second
worst method, beating only HE. Since noise and uncer-
tainty in biological data is certainly expected, be it ex-
pressional or complexes, GSEA is unlikely a superior
alternative to HE.
Fuzzy-FishNET’s performance is comparable to existing
complex-based methods which also rely on the fuzzifica-
tion process e.g. QPSP, FSNET, PFSNET. It does however,
gain power as sample size increases. In D1.2, where n =3
(per class), Fuzzy-FishNET falls behind SNET even
(the earliest incarnation, and least powerful of the RBNAs).
But as sample size increases to n = 6 (per class) in RC1,
then Fuzzy-FishNET beats most methods, is comparable
to FSNET but weaker than PFSNET.
It is fascinating that swapping the differential protein
selection step in favour of a fuzzy weighting system
based on expressional ranks can greatly improve the
precision-recall performance in HE. This is consistently
observed over three sets of simulated data. However, there
is no gold-standard for generating pseudo-complexes, nor
is it known if the lack of biological coherence in the
pseudo-complexes unfairly penalizes certain complex-
based feature-selection approaches. Therefore it is also
essential to consider results based on real data and real
complexes for a comprehensive evaluation.
Reproducibility of technical replicates (Real dataset)
Since technical replicates are present in RC. Each
complex-based feature-selection method can be applied
independently on each replicate. Inter-replicate overlaps
is used as an indicator of complex-based feature-selection
reproducibility.
Reproducibility is a strength of Fuzzy-FishNET (Table 2).
Moreover, it does not make an overly large number of
predictions, hence high-overlaps due to feature inflation
or test hyper-sensitivity are not likely (misleading) contri-
butors to its good performance.
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Feature-selection stability (Real dataset)
Inter-replicate overlap is a good and simple way of evalu-
ating reproducibility given that technical noise should be
the only source of variability (and not due to biological/
clinical heterogeneity). But resampling at various levels
to evaluate feature-selection stability is also possible.
This is useful, as it also allows explicit evaluation of
feature-selection stability in the small sample-size scenario
(most feature-selection methods do not work well when
sample sizes are very small [41]).
Given the full RC dataset, random resamplings of sizes
4, 6 and 8 (representing small to moderate size sample
size scenarios) followed by feature-selection are performed
1000 times. Two aspects are considered: the number of
selected features at each resampling level, and the stability
over all selected features.
It is observed that HE, GSEA, Fuzzy-FishNET are
particularly stable even as resampling size increases
(Fig. 3 Top). While this is a good sign, it does not neces-
sarily mean that the same features are selected each re-
sampling round. Figure 3 (Bottom) shows that for HE and
GSEA, feature-selection stability is particularly low. This

























































































































1 2 3 4 5HE GSEA FFISHNET QPSP SNET 6 FSNET 7 PFSNET
Fig. 2 F-score distributions. The F-score distributions for several network-based methods are shown for three simulated datasets (D1.2, D2.2
and RC1) over three levels of purity (50, 75 and 100%)
Table 2 Selected features for Replicate 1 and 2 are shown
alongside their intersections
HE GSEA FFISHNET QPSP SNET FSNET PFSNET
Replicate 1 4 1 27 86 34 38 45
Replicate 2 6 2 28 75 32 39 46
Overlap 0.25 0.50 0.96 0.66 0.83 0.88 0.93
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is especially so for GSEA, possibly due to the presence
of noise and uncertainty in real data. This supports
the simulation observations.
On the other hand, Fuzzy-FishNET’s feature-selection
stability is second only to that of PFSNET’s. However,
PFSNET is more affected by sampling size increments,
and it also selects considerably more features than
Fuzzy-FishNET. There is a possibility that PFSNET
may suffer from higher hyper-sensitivity and therefore
feature-inflation issues than Fuzzy-FishNET.
Comparing Fuzzy-FishNET with PFSNET
Both PFSNET and Fuzzy-FishNET do very well on repro-
ducibility. In the previous section, as PFSNET selects more
features and appears to be more affected by sampling size
increments, it is possible it is relatively hyper-sensitive,
thus leading to feature-selection inflation.
To determine if this is likely, significant features selected
by PFSNET and Fuzzy-FishNET are compared (Fig. 4a),
revealing deep overlaps (and therefore high agreements)
between both methods. Since there are many more
PFSNET complexes than Fuzzy-FishNET’s, the former’s
p-values distributions for intersecting and non-intersecting
complexes are compared, revealing that Fuzzy-FishNET
selects higher quality complexes (Fig. 4b).
Unlike PFSNET, Fuzzy-FishNET doesn’t assign network
scores for each complex per patient sample. However,
class-discrimination analysis can still be performed using
identified protein expressions found within significant
complexes. Via hierarchical clustering (Ward’s linkage;
Euclidean Distance) coupled to bootstrap resampling [42],
the constituent proteins (found within Fuzzy-FishNET
selected complexes) are highly discriminative between
sample classes (Fig. 4c; red boxes signify highly stable
branches within the tree structure).
Many Fuzzy-FishNET differential complexes are associ-
ated with ribosomal complexes [43], although some are
also associated with the cytoskeleton [44], proteasome
[45] and TNF-alpha complexes [46] (Additional File 3).
Although these are consistent with previous observations
[16], in the absence of actual experimental validation, it is
better to withhold judgement based solely on expected
functionalities with renal cancer.
Fuzzy-FishNET selected complexes that are also class-
relevant, i.e., it doesn’t select features that are weakly
associated with sample classes. The distribution of cross-
validation (CV) accuracies when class labels are real, and
when class labels are shuffled, reveals strong differences
where the prediction model is far more accurate in the
former than in the latter. If the feature-selection method
selects a large number of irrelevant or weakly associated
complexes (hyper-sensitive), then it is expected there will
be little to no differences in CV accuracy between real
and shuffled class labels.
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Fig. 3 Differential complex-selection size and complex-selection stability (Top) Number of selected differential complexes across resampling sizes
of 4, 6 and 8. (Bottom) Corresponding feature-selection stability of differential complexes at each resampling size
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Determining the contribution of Rank Weights
(Fuzzification) towards signal stability
The positive impact of incorporating fuzzification in
Fuzzy-FishNET is not known. It is possible the method
may work just as well with a uniform weight of 1 across
the top alpha%. So, an unweighted version of Fuzzy-
FishNET, FishNET is tested. Note that Fuzzy-FishNET is
analogous to SNET’s uniform weight of 1 for the top
alpha proteins, and 0 for all others.
Figure 5 shows the impact of fuzzification on Fuzzy-
FishNET over three benchmarks: A/the frequency distri-
bution of feature-selection stability, B/The pairwise
feature-selection similarity based on the Jaccard distance
and C/the frequency distribution of false positive rates
based on random class assignment of RC’s normal sam-
ples into two pseudo-classes followed by feature-selection.
Benchmarks A and B are shown over resamplings of sizes
4, 6 and 8. HE is included as a point of reference since it is
a primordial version of Fuzzy-FishNET (and FishNET).
FishNET is not a strong improvement over HE (given its
weaker feature-selection stability), and thus it is clear that
fuzzification has a very strong positive impact on feature-
selection stability, as well as robustness against false posi-
tives. The most informative rank shifts lies within the
most highly ranked proteins, and assigning higher weights
















































































































































































































































































































































Fig. 4 Differential complex agreement between Fuzzy-FishNET and PFSNET a Selected complex features in PFSNET and Fuzzy-FishNET (FFISHNET)
overlap strongly. b Overlapping components are more significant given the p-values (c) The constituent proteins (found within Fuzzy-FishNET
selected complexes) are highly discriminative between sample classes; red boxes signify highly stable branches based on bootstrap resampling
(d) FFISHNET selected features are properly class-discriminative, i.e., provides a high accuracy when actual class differences exist
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Robustness towards alpha adjustment
As with the RBNAs, a valid concern is that alpha adjust-
ments may lead to highly different differential complexes
being selected. Parameterization of alphas however is
not fixed: Increasing alpha from top 10% onwards can
increase sensitivity, but comes at the cost of introducing
more false positives as signal from lower ranked proteins
are introduced into the complex scores (which is why
lower weights for alpha2 are assigned). However, we
would expect the top scoring complexes to be stable.
To examine this concern, the top ranked complexes
generated from top alphas of 10, 20 and 30% is compared
against the default Fuzzy-FishNET setting of alpha1
(top 10%) and alpha2 (top 10–20%) based on overlaps
(A∩B/min(A,B).
The results are generally stable, with overlaps of 62%
at alpha = 10, 64% at alpha = 20, and 69% at alpha = 30
respectively. However, alpha should not be set too low
at the onset, as this will likely introduce many poorer
quality complexes into the significant complex-based
feature set too early into preliminary analysis.
Conclusions
Fuzzy-FishNET is a powerful improvement over its prede-
cessor, the hypergeometric enrichment (HE) approach. It
differs only in the differential protein pre-selection step yet
exhibits high precision-recall in simulated data while being
the most reproducible over evaluations on real data. Based
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Fig. 5 Comparing Fuzzy-FishNET with its non-fuzzy variant, FishNET and HE (a) Feature-selection stability for Fuzzy-FishNET and its non-weighted
variant. HE is added on the left side for comparisons. b Pairwise feature-selection stability (c) False positive evaluations
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properties, Fuzzy-FishNET is a potentially powerful new
entrant amongst complex-based feature-selection methods.
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